Gilead Licensing Deal Expands Remdesivir Access, Capacity
Mylan, Cipla, Hetero Labs, Jubilant, Ferozsons Labs Get Rights
Executive Summary
Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.
You may also be interested in...
Will ViiV’s Regulatory Stance Delay Access To Cabotegravir Despite MPP Deal?
Scrip looks at the contours of MPP’s recent sub-licensing deal for ViiV Healthcare’s cabotegravir with Cipla, Aurobindo and Mylan, along with pricing dynamics and precedents to evaluate a few barriers to access
Will Pfizer's Paxlovid Go The Lagevrio Way In India?
While the Medicines Patent Pool has sub-licensed Paxlovid to multiple Indian firms, it isn’t approved in the country yet. It will get there, but molnupiravir’s sales might give an indication of what is in store for Pfizer’s oral antiviral COVID-19 treatment post a lost opportunity with vaccine Comirnaty.
Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.